Recent Security Class Actions

Biogen Inc. Common Stock (NASDAQ: BIIB)

6 Days left to seek lead plaintiff status.

Company Name:Biogen Inc. Common Stock
Stock Symbol:NASDAQ: BIIB
Class Period Start:02/03/2022
Class Period End (inclusive):02/13/2024
Filing Deadline:07/22/2024

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Biogen had overstated its efforts to enhance its transparency, corporate governance, and compliance controls and procedures, as well as the efficacy of those controls and procedures; (ii) accordingly, Biogen maintained inadequate compliance controls and procedures in connection with its business operations in foreign countries; (iii) Biogen and/or its employees were engaged in unlawful or otherwise improper conduct in several foreign countries; (iv) the foregoing subjected the Company to a heightened risk of governmental and/or regulatory scrutiny and enforcement action, as well as significant legal, financial, and reputational harm; (v) Biogen overstated the strength of its AD-related product portfolio, including the Company's and Eisai's efforts and success in launching and providing access to Leqembi; (vi) Biogen also downplayed the negative impact that the Reata Acquisition would have on its FY 2023 non-GAAP diluted EPS; (vii) all the foregoing were likely to have a significant negative impact on Biogen's 2023 results; and (viii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Biogen Inc. Common Stock (NASDAQ: BIIB) Claim Form

Name(Required)
Address
This field is for validation purposes and should be left unchanged.